Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis

Objectives Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describ...

Full description

Saved in:
Bibliographic Details
Main Authors: Ilja Tchetverikov, J M W Hazes, Hannah den Braanker, Kim Wervers, Adriana M C Mus, Priyanka S Bangoer, Nadine Davelaar, Jolanda Luime, Marijn Vis, Erik Lubberts, Marc R Kok
Format: Article
Language:English
Published: BMJ Publishing Group 2020-09-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/6/2/e001175.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/6/2/e001175.full

Similar Items